[3] mhra.gov.uk)
The primary connection between GLP-1 medications and thyroid considerations relates to a specific safety concern rather than therapeutic benefit
In PIONEER-9, oral semaglutide induced nausea in up to 10% of patients, whereas none of the liraglutide patients had nausea (liraglutide was low-dose however) ( Finally, in a network meta-analysis, several short- and long-acting GLP-1RA were compared regarding efficacy and side effect profile
I forgot to pre-register my experiment, but my hypothesis was that if I took 2 mg [1] of retatrutide per week, I would lose weight
Subsequently, the healthcare provider gradually increases the dosage until it reaches a maintenance dose that provides optimal benefits
Footnotes Supplementary material associated with this article can be found in the online version, at doi:10.1016/j.ajpc.2023.100502